Viral vector manufacturing decisions can make or break your cell and gene therapy programs.
As the cell and gene therapy (CGT) landscape becomes more crowded and timelines, budgets and regulatory expectations tighten, small and mid-size biotechs face increasing pressure to scale smarter, not just faster. Early choices around process design, analytics and partners have a lasting impact on cost, risk and time to market.
This guide explores how biotechs developing CGTs relying on AAV, lentiviral and retroviral vectors can navigate scale-up challenges with confidence. Drawing on real-world manufacturing experience, it outlines how to balance speed, scalability and regulatory readiness on the path to commercialization and explores how a “perfect-fit” CDMO partner can simplify the road ahead.
You’ll learn how to:
- Make early process and analytical decisions that support scalable, GMP-ready manufacturing
- Balance speed, cost and regulatory expectations without creating downstream risk
- Plan viral vector scale-up strategies for AAV, lentiviral and retroviral programs
- Avoid common pitfalls that delay timelines and increase rework as programs advance
- Evaluate what a “perfect-fit” CDMO looks like for small and mid-size biotech teams
Download the guide to learn how the right strategy and the right partner can help turn viral vector manufacturing from a bottleneck into a competitive advantage.
